KCS Wealth Advisory lowered its holdings in shares of Danaher Co. (NYSE:DHR) by 40.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,718 shares of the conglomerate’s stock after selling 1,188 shares during the quarter. KCS Wealth Advisory’s holdings in Danaher were worth $264,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Howe & Rusling Inc. boosted its holdings in Danaher by 116.3% during the 3rd quarter. Howe & Rusling Inc. now owns 186 shares of the conglomerate’s stock valued at $27,000 after acquiring an additional 100 shares during the period. NewSquare Capital LLC purchased a new position in Danaher during the 4th quarter valued at $40,000. Pinnacle Bank boosted its holdings in Danaher by 52.3% during the 3rd quarter. Pinnacle Bank now owns 262 shares of the conglomerate’s stock valued at $38,000 after acquiring an additional 90 shares during the period. Private Ocean LLC purchased a new stake in shares of Danaher in the 3rd quarter worth $39,000. Finally, City Holding Co. lifted its holdings in shares of Danaher by 48.5% in the 3rd quarter. City Holding Co. now owns 306 shares of the conglomerate’s stock worth $44,000 after buying an additional 100 shares during the period. Institutional investors own 77.99% of the company’s stock.
Shares of NYSE DHR opened at $160.80 on Thursday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.43 and a quick ratio of 3.09. The stock has a market capitalization of $115.92 billion, a P/E ratio of 35.58, a price-to-earnings-growth ratio of 2.57 and a beta of 0.93. Danaher Co. has a 1-year low of $104.16 and a 1-year high of $162.37. The business has a fifty day moving average price of $151.92 and a 200 day moving average price of $143.27.
Danaher (NYSE:DHR) last issued its quarterly earnings data on Thursday, October 24th. The conglomerate reported $1.16 earnings per share for the quarter, topping analysts’ consensus estimates of $1.15 by $0.01. The firm had revenue of $5.04 billion during the quarter, compared to analysts’ expectations of $5.02 billion. Danaher had a return on equity of 11.42% and a net margin of 12.13%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.10 EPS. As a group, equities research analysts anticipate that Danaher Co. will post 4.66 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date of this dividend is Thursday, December 26th. Danaher’s dividend payout ratio (DPR) is currently 15.04%.
Several equities research analysts have weighed in on DHR shares. Credit Suisse Group upped their target price on Danaher from $151.00 to $160.00 and gave the stock an “outperform” rating in a report on Thursday, December 19th. Wolfe Research set a $154.00 target price on Danaher and gave the stock a “buy” rating in a report on Friday, October 25th. ValuEngine cut Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Needham & Company LLC upped their target price on Danaher from $152.00 to $167.00 and gave the stock a “buy” rating in a report on Thursday, January 2nd. Finally, Wells Fargo & Co started coverage on Danaher in a report on Tuesday, January 7th. They issued an “overweight” rating and a $170.00 target price for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $159.69.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Story: What is the Beige Book?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.